Delving into the Latest Updates on Eli Lilly Japan KK with Synapse

Overview

Tags

Other Diseases

Nervous System Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Monoclonal antibody

Hormone

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	7
Endocrinology and Metabolic Disease	5
Immune System Diseases	5
Neoplasms	4
Infectious Diseases	3
Hemic and Lymphatic Diseases	2

Top 5 Drug Type	Count

Small molecule drug	5
Monoclonal antibody	3
Hormone	1
Biosimilar	1
Recombinant polypeptide	1

Top 5 Target	Count

GIPR x GLP-1R	1
5-HT1F receptor(Serotonin 1f (5-HT1f) receptor)	1
GHR(Growth hormone receptor)	1
RET(Tyrosine-protein kinase receptor RET)	1
DHFR x GART x TYMS	1

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine (I4V-MC-JAIN)

Start Date15 May 2018

Sponsor / Collaborator

Eli Lilly Japan KK

100 Clinical Results associated with Eli Lilly Japan KK

Login to view more data

0 Patents (Medical) associated with Eli Lilly Japan KK

Login to view more data

324

Literatures (Medical) associated with Eli Lilly Japan KK

01 Aug 2024·Rheumatology and Therapy

Correction: Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)

Author: Dobashi, Hiroaki ; Morisaki, Yoji ; Kameda, Hideto ; Hagimori, Kohei ; Holzkämper, Thorsten ; Konomi, Ayako

01 Jul 2024·Targeted Oncology

Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study

Article

Author: Jin, Long ; Sunakawa, Yu ; Cai, Zhihong ; Tanizawa, Yoshinori ; Wang, Chaochen ; Piao, Yongzhe ; Kagawa, Yoshinori

BACKGROUNDOxaliplatin-containing adjuvant regimens (folinic acid, fluorouracil, and oxaliplatin/capecitabine and oxaliplatin [FOLFOX/CAPOX]) are used after curative resection of colorectal cancer (CRC). However, real-world evidence regarding treatment sequences and outcomes in patients with early recurrence CRC after adjuvant chemotherapy is limited.OBJECTIVEWe aimed to describe the patient characteristics, treatment sequence, and overall duration of second-line (2L) therapy in patients with early recurrence CRC who received adjuvant chemotherapy (FOLFOX/CAPOX) followed by folinic acid, fluorouracil, and irinotecan (FOLFIRI) + anti-angiogenesis drugs (AA) or FOLFIRI + anti-epidermal growth factor receptor (EGFR) antibodies.METHODSThis retrospective study analyzed Japanese administrative data from November 2014 to March 2023 of adult patients who underwent CRC resection surgery, started FOLFOX/CAPOX ≤3 months (mo) after surgery, and had early CRC recurrence. Early recurrence was defined as initiation of FOLFIRI+AA or FOLFIRI+anti-EGFR antibodies as 2L therapy, ≤12 mo of discontinuing adjuvant chemotherapy. Patient characteristics, treatment sequence, median time to treatment discontinuation (mTTD), i.e., duration between the start and end dates of 2L therapy (Kaplan-Meier method), and factors associated with 2L time to treatment discontinuation constituted the study outcomes (Cox regression model). Subgroup analyses were performed for timing of early CRC recurrence (≤6 mo and 6-12 mo) and tumor sidedness.RESULTSAmong the 832 selected patients (median age [minimum-maximum] 67 (24-86) years, 56.4% male), CAPOX (71.3%) was more commonly used than FOLFOX (28.7%) as adjuvant therapy. FOLFIRI+AA (72.5%) was used more commonly than FOLFIRI+anti-EGFR antibodies (27.5%) in 2L. AA and anti-EGFR antibodies groups had similar mTTD: 6.2 mo (95% confidence interval 5.8, 6.9) and 6.1 mo (95% confidence interval 5.2, 7.4). Age ≥70 years showed significant association with shorter 2L treatment duration (hazard ratio 1.2, 95% confidence interval 1.0, 1.4; p = 0.03). The AA cohort's mTTD was numerically shorter in the ≤6 mo recurrence subgroup compared with the 6-12 mo recurrence subgroup (6.1 mo vs 8.1 mo); the anti-EGFR antibodies cohort had similar mTTD (5.8 mo vs 6.2 mo). The AA and anti-EGFR antibodies cohorts also had similar mTTD in the left-sided CRC subgroup (6.5 mo vs 6.2 mo), but not in the right-sided subgroup (5.6 mo vs 3.9 mo).CONCLUSIONSThis is the first administrative data-based real-world evidence on treatment sequence and outcomes for patients with early recurrence CRC treated with FOLFIRI+AAs or FOLFIRI+ anti-EGFR antibodies after adjuvant FOLFOX/CAPOX therapy in Japan. Both regimens had similar TTD, but relapse timing and tumor sidedness may influence their efficacy.

01 Jun 2024·Neurology and Therapy

Donanemab in Japanese Patients with Early Alzheimer’s Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial

Article

Author: Katayama, Sadao ; Hatakeyama, Naohisa ; Sims, John R ; Fujikoshi, Shinji ; Sato, Shoichiro ; Katagiri, Hideaki

INTRODUCTIONDonanemab, a monoclonal antibody directed against an insoluble, modified, N-terminal truncated form of amyloid beta, demonstrated efficacy and safety in patients with early, symptomatic Alzheimer's disease (AD) in the phase 3 TRAILBLAZER-ALZ 2 trial. Here, we report clinical outcomes, biomarkers, and safety results for the Japanese subpopulation.METHODSTRAILBLAZER-ALZ 2 (N = 1736) was conducted in eight countries, including Japan (enrollment June 2020-November 2021; database lock April 2023). Participants (60-85 years) with early, symptomatic AD (mild cognitive impairment/mild dementia), Mini-Mental State Examination score 20-28, and confirmed amyloid and tau pathology were randomized 1:1 (stratified by tau status) to intravenous donanemab (700 mg for three doses, then 1400 mg/dose) or placebo every 4 weeks for 72 weeks. Primary outcome was change from baseline to week 76 in integrated Alzheimer's Disease Rating Scale (iADRS) score. Other outcomes included clinical measures of cognitive and functional impairment, biomarkers, and safety.RESULTSOf 88 Japanese participants (43 placebo, 45 donanemab), 7 in each group discontinued. Least-squares mean (LSM) change from baseline in iADRS score at week 76 was smaller with donanemab than with placebo in the combined (low-medium tau and high tau) and low-medium tau (N = 76) subpopulations (LSM change difference: 4.43 and 3.99, representing 38.8% and 40.2% slowing of disease progression, respectively). Slowing of AD progression with donanemab was also observed for other clinical outcomes. Marked decreases in amyloid plaque and plasma phosphorylated tau 217 were observed; amyloid clearance (< 24.1 Centiloids) was observed in 83.3% of the combined donanemab and 0% of the combined placebo groups. Amyloid-related imaging abnormalities of edema/effusions occurred in ten (22.2%) donanemab-treated participants (one [2.2%] symptomatic) and one (2.3%) placebo-treated participant.CONCLUSIONSThe overall efficacy and safety of donanemab in Japanese participants were similar to the global TRAILBLAZER-ALZ 2 population.TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT04437511.

100 Deals associated with Eli Lilly Japan KK

Login to view more data

100 Translational Medicine associated with Eli Lilly Japan KK

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

11

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Teriparatide(Eli Lilly) ( PTH1R )	Osteoporosis More	Approved
Pirtobrutinib ( BTK C481S )	Mantle cell lymphoma refractory More	Approved
Lebrikizumab ( IL-13 )	Dermatitis, Atopic More	Approved
Donanemab-AZBT ( pGlu3Aβ )	Alzheimer Disease More	Approved
Tirzepatide ( GIPR x GLP-1R )	Diabetes Mellitus, Type 2 More	Approved